Maxim Group Analysts Give Galmed Pharmaceuticals (GLMD) a $14.00 Price Target
Galmed Pharmaceuticals (NASDAQ:GLMD) has been given a $14.00 price objective by equities researchers at Maxim Group in a note issued to investors on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective indicates a potential upside of 38.89% from the company’s current price.
GLMD has been the subject of a number of other reports. Roth Capital began coverage on Galmed Pharmaceuticals in a research note on Wednesday, November 15th. They set a “buy” rating and a $32.00 price target for the company. ValuEngine lowered Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Seaport Global Securities reissued a “buy” rating and set a $19.00 price target on shares of Galmed Pharmaceuticals in a research note on Friday, October 6th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Galmed Pharmaceuticals in a research note on Friday, October 27th. Finally, Zacks Investment Research lowered Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $18.30.
Shares of Galmed Pharmaceuticals (NASDAQ:GLMD) traded up $0.69 during mid-day trading on Wednesday, hitting $10.08. The company had a trading volume of 104,406 shares, compared to its average volume of 91,250. Galmed Pharmaceuticals has a 52-week low of $3.54 and a 52-week high of $10.70. The company has a market cap of $127.84, a price-to-earnings ratio of -8.26 and a beta of 2.46.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.